World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
72
Citations
22674
World Ranking
2188
National Ranking
55

Alfred Zippelius publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Alfred Zippelius sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 239 publications — 48th percentile

48% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Alfred Zippelius D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Alfred Zippelius sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 72 D-Index — 56th percentile

56% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Alfred Zippelius is affiliated with the University Hospital of Basel in Switzerland and is active in the fields of Medicine, Immunology and Microbiology, and Biochemistry, Genetics and Molecular Biology. Their research output includes a significant focus on Oncology, Immunology, Molecular Biology, Pulmonary and Respiratory Medicine, and Cancer Research.

The main research topics covered by their work include Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immunotherapy and Immune Responses, Immune Cell Function and Interaction, Immune cells in cancer, Lung Cancer Treatments and Mutations, and Cancer, Hypoxia, and Metabolism.

Some recent papers authored by Alfred Zippelius include:

  • CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors, 2020, Nature Immunology
  • Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion, 2020, Nature Immunology
  • SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial, 2021, Journal of Clinical Oncology
  • An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer, 2021, Nature Medicine
  • Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy, 2021, Nature

Frequent co-authors collaborating with Alfred Zippelius include Heinz Läubli, Nicole Kirchhammer, Marcel P. Trefny, Petra Herzig, and Mélanie Buchi.

Their publications are commonly found in several notable venues:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Journal for ImmunoTherapy of Cancer
  • Regular and Young Investigator Award Abstracts
  • Frontiers in Immunology
  • Journal of Clinical Oncology

Best Publications

  • A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade

    Daniela S. Thommen;Daniela S. Thommen;Viktor H. Koelzer;Petra Herzig;Andreas Roller

  • RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell Types.

    Gianni Monaco;Gianni Monaco;Gianni Monaco;Bernett Lee;Weili Xu;Seri Mustafah

  • Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.

    Christopher S. Garris;Sean P. Arlauckas;Rainer H. Kohler;Marcel P. Trefny

  • CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors

    Haiping Wang;Fabien Franco;Yao Chen Tsui;Xin Xie

  • Disturbed mitochondrial dynamics in CD8 + TILs reinforce T cell exhaustion

    Yi-Ru Yu;Yi-Ru Yu;Hana Imrichova;Haiping Wang;Haiping Wang;Tung Chao;Tung Chao

  • Four functionally distinct populations of human effector-memory CD8+ T lymphocytes.

    Pedro Romero;Alfred Zippelius;Alfred Zippelius;Isabel Kurth;Mikaël J. Pittet;Mikaël J. Pittet

  • Effector Function of Human Tumor-Specific CD8 T Cells in Melanoma Lesions: A State of Local Functional Tolerance

    Alfred Zippelius;Pascal Batard;Verena Rubio-Godoy;Gilles Bioley

  • Selective Survival of Naturally Occurring Human CD4+CD25+Foxp3+ Regulatory T Cells Cultured with Rapamycin

    Laura Strauss;Laura Strauss;Theresa L. Whiteside;Ashley Knights;Christoph Bergmann

  • Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors

    Daniela Stefanie Thommen;Jens Schreiner;Philipp Müller;Petra Herzig

  • Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.

    Fiamma Berner;David Bomze;Stefan Diem;Omar Hasan Ali

  • Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow.

    A Zippelius;P Kufer;G Honold;M W Köllermann

  • Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade.

    Philipp Müller;Matthias Kreuzaler;Tarik Khan;Daniela S. Thommen;Daniela S. Thommen

  • Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma

    Heinz Läubli;Heinz Läubli;Cathrin Balmelli;Matthias Bossard;Otmar Pfister

  • The immune system and cancer evasion strategies: therapeutic concepts

    S. Muenst;H. Läubli;H. Läubli;S. D. Soysal;A. Zippelius;A. Zippelius

  • An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer.

    Paula Voabil;Marjolein de Bruijn;Lisanne M. Roelofsen;Sanne H. Hendriks;Sanne H. Hendriks

  • Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy

    Ana Luísa Correia;Ana Luísa Correia;Ana Luísa Correia;Joao C. Guimaraes;Joao C. Guimaraes;Priska Auf der Maur;Priska Auf der Maur;Duvini De Silva;Duvini De Silva;Duvini De Silva

  • Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells

    Michal A. Stanczak;Shoib S. Siddiqui;Marcel P. Trefny;Daniela S. Thommen

  • Phenotypic Characteristics of Cell Lines Derived from Disseminated Cancer Cells in Bone Marrow of Patients with Solid Epithelial Tumors: Establishment of Working Models for Human Micrometastases

    Elmar Putz;Klaus Witter;Sonja Offner;Peter Stosiek

  • Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.

    Christina Claus;Claudia Ferrara;Wei Xu;Johannes Sam

  • Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

    Alexandros Papachristofilou;Madeleine M. Hipp;Ute Klinkhardt;Martin Früh

  • Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions.

    Nathalie Rufer;Alfred Zippelius;Pascal Batard;Mikaël J. Pittet

  • Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.

    Pedro Romero;Danila Valmori;Mikael J. Pittet;Alfred Zippelius

Frequent Co-Authors

Mikael J. Pittet
Mikael J. Pittet University of Geneva
Pedro Romero
Pedro Romero University of Lausanne
Daniel E. Speiser
Daniel E. Speiser University of Lausanne
Lukas Bubendorf
Lukas Bubendorf University Hospital of Basel
Jean-Charles Cerottini
Jean-Charles Cerottini University of Lausanne
Alexander Knuth
Alexander Knuth University of Zurich
Walter Weder
Walter Weder University of Zurich
Solange Peters
Solange Peters University Hospital of Lausanne
Danila Valmori
Danila Valmori University of Nantes
Philippe Guillaume
Philippe Guillaume University of Lausanne

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare fields can open diverse career opportunities. Many professionals expand their expertise by pursuing advanced nursing degrees, such as Psychiatric Mental Health Nurse Practitioner programs. Affordable options like the cheapest online pmhnp programs enable learners to enter this specialized area without excessive financial strain.

Understanding salary prospects is critical when planning your career. For instance, among Doctor of Nursing Practice specialties, some are notably lucrative. Insights into the highest paid dnp specialties help guide decisions toward roles with strong earning potential and job stability.

Certifications play a vital role in career advancement. Nurses transitioning from Family Nurse Practitioner roles might consider obtaining an acute care np certification to work in more intensive clinical settings, which aligns well with the fast-paced demands of immunology-related healthcare.

For accelerated career paths, many students pursue accelerated np programs online. These programs are designed for efficiency, allowing qualified individuals to quickly advance their credentials and impact patient care in immunology and related fields.

Best Scientists Citing Alfred Zippelius

Trending Scientists

Recently Published Articles